Navigation Links
Beckman Coulter, Inc. Announces Common Stock Offering
Date:5/18/2009

ORANGE COUNTY, Calif., May 18 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, today announced it has commenced a public offering of shares of its common stock, to finance in part the previously announced acquisition of the diagnostic systems portion of Olympus Corporation's Life Science business, or the acquisition. The Company expects to raise proceeds of approximately $235 million in the offering, or $250 million if the over-allotment option granted to the underwriters is exercised in full. Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

The offering is being made under Beckman Coulter's existing shelf registration statement filed with the Securities and Exchange Commission. In connection with the offering of its common stock, Beckman Coulter expects to enter into forward sale agreements with each of Morgan Stanley & Co. Incorporated and Goldman, Sachs & Co. or their respective affiliates, whom we refer to as the forward purchasers. The forward purchasers will borrow and sell to the public through the underwriters shares of Beckman Coulter's common stock. The forward sale agreements provide for settlement on a date or dates to be specified by Beckman Coulter at the public offering price less the underwriting discount (subject to adjustment). The settlement of the forward sale agreements is expected to occur in conjunction with the closing of the acquisition, but in no event later than twelve months following the date of the common stock offering. Subject to certain exceptions, Beckman Coulter has the right to elect physical, cash or net stock settlement of the forward sale agreements.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of the common stock or any other security of Beckman Coulter, nor shall there be any sale of the common stock in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such jurisdiction. When available, copies of the prospectus and related prospectus supplement may be obtained from Morgan Stanley & Co. Incorporated, Prospectus Department, 1585 Broadway, New York, NY 10036 and Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004 Attention: Prospectus Department (212-902-1171).

Certain statements in this news release may be deemed to include forward-looking statements, such as statements that relate to the common stock offering and whether Beckman Coulter will consummate the offering. Forward-looking statements are typically identified by words or phrases, such as "believe," "expect," "anticipate," "intend," "estimate," "may increase," "may fluctuate," "plan," "goal," "target," "strategy," and similar expressions or future or conditional verbs such as "may," "will," "should," "would," and "could." These statements are based on current expectations, forecasts and assumptions and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, including economic, market and monetary policy risks; operational risks; investment performance, fiduciary, and asset services risks; credit risks; liquidity risks; holding company risks; regulation risks; litigation risks; tax and accounting risks; strategic and competitive risks; and reputation risks. For a further list and description of risks and uncertainties associated with Beckman Coulter's business, see reports filed by Beckman Coulter with the Securities and Exchange Commission, including the "Risk Factors" section in the most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Beckman Coulter disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Contact:    Cynthia Skoglund                   (714) 773-7620
                Manager, Investor Relations


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval
2. Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Beckman Coulter Announces Third Quarter 2008 Results
5. Beckman Coulter to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens
7. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
8. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
9. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
10. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
11. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional ... it has enlisted New York City-based sports and entertainment marketing firm Leverage Agency ... sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ever title ...
(Date:3/29/2017)... ... 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE ... will serve as the official title sponsor of the Baltimore Women’s Classic, the largest ... of women will walk or run the course around the Baltimore Inner Harbor. Mercy ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general dentist in ... pediatric patients, with or without a referral. Dr. Cotey knows that interceptive orthodontics ... and experience. When patients receive early treatment, they may achieve straight teeth with less ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Global intravenous (IV) iron and oral iron ... growing at a CAGR of 5%. Iron ... to treat anemia or other iron deficiencies. Oral iron supplements ... However, in some cases, oral administrations are not capable of ... iron therapy comes into the picture. Global Intravenous ...
(Date:3/29/2017)... DES MOINES, Iowa , March 29, 2017 ... Iowa Lt. Gov. Kim Reynolds , Department of Public ... Control Policy Director Steve Lukan in announcing the ... at all CVS Pharmacy locations in Iowa.  CVS Health has ... that allows CVS Pharmacy to expand access to ...
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
Breaking Medicine Technology: